Apeloa Pharmaceutical Co.,Ltd Apeloa Pharmaceutical Co.,Ltd

Apeloa Pharmaceutical Co.,Ltd

000739

Rang in Aktien #4290
Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical... Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical enterprise, specializing in the discovery, development, production, and global distribution of a diverse range of medicinal products. Its market reach spans China and various international territories. The company strategically focuses its product portfolio on several critical medical fields, including cardiovascular and cerebrovascular health, anti-infective treatments, antiviral therapies, and oncology (cancer treatment), alongside other therapeutic categories. Apeloa's offerings encompass finished pharmaceutical preparations, raw material intermediates (active pharmaceutical ingredients and their precursors), and veterinary medicines. These products are primarily recognized and sold under key brands such as Tianliwei, Beshin, Yosemade, and Jutai, among others. Furthermore, the company extends its expertise to other pharmaceutical businesses by providing contract research, development, and manufacturing (CDMO) services. The corporate headquarters for Apeloa Pharmaceutical Co.,Ltd are located in Dongyang, China.
Aktienkurs
$3.13
Marktkapitalisierung
$3.62B
Veränderung (1 Tag)
-1.42%
Veränderung (1 Jahr)
46.59%
Land
CN
Handel Apeloa Pharmaceutical Co.,Ltd (000739)

Kategorie

Healthcare
Aktien-Split-Historie für Apeloa Pharmaceutical Co.,Ltd (000739)
Die Aktie Apeloa Pharmaceutical Co.,Ltd (Symbol: 000739) durchlief insgesamt 6 Aktiensplits.
Der letzte Aktiensplit fand am May 30, 2014 statt.
Eine 000739-Aktie, die vor dem Jul 02, 1998 gekauft wurde, entspricht heute 10.53 000739-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
2014-05-30 13:10 x1.3 x10.53
2013-06-21 2:1 x2 x8.1
2007-07-05 3:2 x1.5 x4.05
2006-02-15 5:4 x1.25 x2.7
1999-05-28 9:5 x1.8 x2.16
1998-07-02 6:5 x1.2 x1.2
Aktiensplits ähnlicher Unternehmen oder Wettbewerber